The Medicines Company (MDCO) : Thursdays money flow data in The Medicines Company (MDCO) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $4.69 million, whereas, $2.21 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 2.13, in favor of the bulls. The total money flow into the stock was $2.49 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $2.04 million. The total value of block trades done on upticks was $2.04 million. The Medicines Company (MDCO) fell $0.02 and traded at $35.8, down -0.06% for the day, over previous days close. On a weekly basis, the shares are 2.58% over the previous weeks close.
The stock has recorded a 20-day Moving Average of 3.38% and the 50-Day Moving Average is 0.26%. Shares have rallied 7.29% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $43.79 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $35.81 and the 200 Day Moving Average price is recorded at $34.11.
The Medicines Company (NASDAQ:MDCO): The stock opened at $35.94 on Thursday but the bulls could not build on the opening and the stock topped out at $36.19 for the day. The stock traded down to $35.11 during the day, due to lack of any buying support eventually closed down at $35.77 with a loss of -0.14% for the day. The stock had closed at $35.82 on the previous day. The total traded volume was 628,450 shares.
In an insider trading activity, Cox Christopher T, officer (EVP & Chief Corp. Dev. Officer) of Medicines Co /De, executed a transaction worth $1,729,956 on June 8, 2016. A total of 45,985 shares were purchased at an average price of $37.62. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.